Compare Stocks: VRCA, IKT, VNDA, and AMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.63 -1.7%	$14.06	$12.96 ▼ $20.90	$287.91M	0.76	76,644 shs	50,664 shs
IKT Inhibikase Therapeutics	$2.30	$2.34	$1.33 ▼ $2.61	$320.93M	0.95	1.15 million shs	3.21 million shs
VNDA Vanda Pharmaceuticals	$5.13 +0.4%	$5.31	$4.27 ▼ $9.94	$310.18M	0.64	1.55 million shs	1.66 million shs
VRCA Verrica Pharmaceuticals	$4.45 -4.3%	$5.22	$3.28 ▼ $9.82	$76.45M	1.49	93,563 shs	113,179 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	+0.22%	-1.21%	-1.84%	-13.47%	-5.00%
IKT Inhibikase Therapeutics	-0.43%	-1.29%	-4.17%	+25.68%	+47.44%
VNDA Vanda Pharmaceuticals	+2.20%	+1.39%	-6.07%	-11.90%	+16.40%
VRCA Verrica Pharmaceuticals	+2.65%	-6.06%	-0.64%	-17.41%	+5.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.63 -1.7%	$14.06	$12.96 ▼ $20.90	$287.91M	0.76	76,644 shs	50,664 shs
IKT Inhibikase Therapeutics	$2.30	$2.34	$1.33 ▼ $2.61	$320.93M	0.95	1.15 million shs	3.21 million shs
VNDA Vanda Pharmaceuticals	$5.13 +0.4%	$5.31	$4.27 ▼ $9.94	$310.18M	0.64	1.55 million shs	1.66 million shs
VRCA Verrica Pharmaceuticals	$4.45 -4.3%	$5.22	$3.28 ▼ $9.82	$76.45M	1.49	93,563 shs	113,179 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	+0.22%	-1.21%	-1.84%	-13.47%	-5.00%
IKT Inhibikase Therapeutics	-0.43%	-1.29%	-4.17%	+25.68%	+47.44%
VNDA Vanda Pharmaceuticals	+2.20%	+1.39%	-6.07%	-11.90%	+16.40%
VRCA Verrica Pharmaceuticals	+2.65%	-6.06%	-0.64%	-17.41%	+5.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.33	Sell	$13.00	-4.62% Downside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	134.78% Upside
VNDA Vanda Pharmaceuticals	2.50	Moderate Buy	$13.70	167.06% Upside
VRCA Verrica Pharmaceuticals	2.40	Hold	$12.67	184.64% Upside

Current Analyst Ratings Breakdown

Latest VRCA, IKT, VNDA, and AMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	VRCA Verrica Pharmaceuticals	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/17/2026	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$21.00 ➝ $20.00
8/10/2026	VNDA Vanda Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $12.00
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/17/2026	AMRN Amarin	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	VRCA Verrica Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	IKT Inhibikase Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$186.23M	1.55	$0.36 per share	38.34	$22.07 per share	0.62
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$2.30 per share	N/A
VNDA Vanda Pharmaceuticals	$215.72M	1.44	N/A	N/A	$5.54 per share	0.93
VRCA Verrica Pharmaceuticals	$30.32M	2.52	N/A	N/A	$1.55 per share	2.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)
VRCA Verrica Pharmaceuticals	-$17.89M	-$1.67	N/A	N/A	N/A	-102.84%	-407.11%	-70.17%	11/13/2026 (Estimated)

Latest VRCA, IKT, VNDA, and AMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.67	2.67
IKT Inhibikase Therapeutics	N/A	15.82	15.82
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60
VRCA Verrica Pharmaceuticals	0.18	1.45	1.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
IKT Inhibikase Therapeutics	3.81%
VNDA Vanda Pharmaceuticals	88.14%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
AMRN Amarin	4.21%
IKT Inhibikase Therapeutics	7.10%
VNDA Vanda Pharmaceuticals	10.70%
VRCA Verrica Pharmaceuticals	52.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	80	21.12 million	20.23 million	Optionable
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A
VNDA Vanda Pharmaceuticals	533	60.46 million	53.99 million	Optionable
VRCA Verrica Pharmaceuticals	76	17.18 million	8.09 million	No Data

VRCA, IKT, VNDA, and AMRN Headlines

Recent News About These Companies

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Hold" by Analysts

September 14, 2026 | marketbeat.com

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

September 10, 2026 | globenewswire.com

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data ...

August 27, 2026 | finance.yahoo.com

Lake Street Capital Begins Coverage on Verrica Pharmaceuticals (NASDAQ:VRCA)

August 27, 2026 | marketbeat.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

August 27, 2026 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts

August 20, 2026 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Buys 4,200 Shares

August 19, 2026 | insidertrades.com

Verrica (VRCA) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 6, 2026 | manilatimes.netM

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

August 6, 2026 | finance.yahoo.com

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum ...

July 21, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

July 21, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...

June 23, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals Announces First U.S. and Japanese Patients Dosed in Phase 3 COVE-3 Trial of YCANTH for Common Warts

June 22, 2026 | quiverquant.comQ

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

June 22, 2026 | globenewswire.com

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026 | globenewswire.com

Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

May 13, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, IKT, VNDA, and AMRN Company Descriptions

Amarin NASDAQ:AMRN

$13.63 -0.24 (-1.73%)

Closing price 04:00 PM Eastern

Extended Trading

$13.63 0.00 (0.00%)

As of 04:10 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Inhibikase Therapeutics NASDAQ:IKT

$2.30 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.30 0.00 (-0.22%)

As of 04:15 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Vanda Pharmaceuticals NASDAQ:VNDA

$5.13 +0.02 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$5.12 0.00 (-0.10%)

As of 04:38 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Verrica Pharmaceuticals NASDAQ:VRCA

$4.45 -0.20 (-4.30%)

Closing price 04:00 PM Eastern

Extended Trading

$4.52 +0.07 (+1.57%)

As of 04:10 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRCA, IKT, VNDA, and AMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRCA, IKT, VNDA, and AMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRCA, IKT, VNDA, and AMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, IKT, VNDA, and AMRN Company Descriptions

Amarin NASDAQ:AMRN

Inhibikase Therapeutics NASDAQ:IKT

Vanda Pharmaceuticals NASDAQ:VNDA

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRCA, IKT, VNDA, and AMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRCA, IKT, VNDA, and AMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRCA, IKT, VNDA, and AMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, IKT, VNDA, and AMRN Company Descriptions

Amarin NASDAQ:AMRN

Inhibikase Therapeutics NASDAQ:IKT

Vanda Pharmaceuticals NASDAQ:VNDA

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools